Here is a clinical summary about the new myeloma drug I wrote about last night, perifosine, from a Website named “drugdevelopment-technology.com:”
KRX-0401 (perifosine) is a potential oral anti-cancer agent that suppresses the pathways associated with the programmed growth, death, differentiation and survival of cells. Developed by Keryx, the drug is most effective in modulating Akt, as well as JNK and MAPK pathways.
In clinical trials conducted in the US and Europe, perifosine has treated more than 1,800 cancer patients. When used as a single agent and also in combination with novel agents, KRX-0401 helps in treating patients with advanced cancer.
KRX-0401 (perifosine) is undergoing its Phase III clinical trials for the treatment of refractory multiple myeloma, in combination with placebo, and Phase II trials for multiple other forms of cancer.
The clinical trial results of the combined Phase I/II study were announced in February 2009. In conjunction with bortezomib and dexamethasone, perifosine exhibited an impressive response rate and time-to-progression (TTP). Nearly 83% of the patients who were evaluated were found to have attained stable disease or better. The overall response rate and TTP of bortezomib-relapsed patients also improved to 55%. Patients in whom the disease relapsed after taking a bortezomib-based treatment showed an average TTP of 8.5 months. The average TTP of all the evaluable patients was 6.4 months.
As I wrote last night, this is one of the exciting new anti-myeloma drugs which excites Dr. Kenneth Anderson of Harvard. Vorinostat is another. I will get you updated info about vorinostat I viewed at ASH tomorrow.
Feel good and keep smiling! Pat